CompletedPhase 2NCT01088373
Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q
Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Groupe Francophone des Myelodysplasies
- Principal Investigator
- Lionel ADES, MDGFM
- Intervention
- Azacitidine combined to Lenalidomide(drug)
- Enrollment
- 50 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2010 – 2016
Study locations (30)
- Hôpital kremlin Bicêtre, Le Kremlin-Bicêtre, IDF, France
- Chu Brabois, Nancy, Vandoeuvre, France
- CHU d'Amiens, Amiens, France
- CHU Angers, Angers, France
- Hôpital de la cote basque, Bayonne, France
- Hôpital Avicenne, Bobigny, France
- CHU Haut-Lévèque, Bordeaux, France
- CH René Dubos, Cergy-Pontoise, France
- CHU de, Clermont-Ferrand, France
- Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France
- CHU Henri Mondor, Créteil, France
- CHU de Grenoble, Grenoble, France
- CH Le mans, Le Mans, France
- Centre Hospitalier de Lens, Lens, France
- CHRU de Limoges, Limoges, France
- +15 more locations on ClinicalTrials.gov
Collaborators
Celgene
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01088373 on ClinicalTrials.govOther trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Additional recruiting or active studies for the same condition.